BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/17/2026 8:23:32 AM | Browse: 2 | Download: 0
 |
Received |
|
2026-03-05 02:14 |
|
Peer-Review Started |
|
2026-03-05 02:14 |
|
First Decision by Editorial Office Director |
|
2026-03-20 11:34 |
|
Return for Revision |
|
2026-03-20 11:34 |
|
Revised |
|
2026-04-02 23:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-20 02:56 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-20 07:47 |
|
Articles in Press |
|
2026-04-20 07:47 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-10 06:13 |
|
Publish the Manuscript Online |
|
2026-07-17 08:23 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Extending the evidence on ustekinumab safety in Crohn’s disease: A pharmacovigilance disproportionality analysis of FAERS data
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qiu-Han Yao and Wei-Yu Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wei-Yu Yang, Assistant Professor, MD, PhD, Department of Thoracic Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201 Hubin South Road, Siming District, Xiamen 361000, Fujian Province, China. yangweiyu@alu.cau.edu.cn |
| Key Words |
Crohn’s disease; Ustekinumab; Safety; Pharmacovigilance; Adverse event |
| Core Tip |
Compared with the small clinical cohort reported earlier, this study provides a broader real-world safety evaluation of ustekinumab in Crohn’s disease using 21441 United States Food and Drug Administration Adverse Event Reporting System reports. Infections were the predominant reported adverse events (AEs), and additional cardiovascular and neuropsychiatric disproportionality signals were detected. Because 28.4% of reported AEs occurred within 60 days and nearly half after 180 days, both early and extended monitoring are important. These findings offer practical guidance for individualized safety surveillance during ustekinumab treatment. |
| Publish Date |
2026-07-17 08:23 |
| Citation |
Yao QH, Yang WY. Extending the evidence on ustekinumab safety in Crohn’s disease: A pharmacovigilance disproportionality analysis of FAERS data. World J Gastroenterol 2026; 32(29): 120684
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i29/120684.htm |
| DOI |
https://doi.org/10.3748/wjg.120684 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
